Silvia Zamboni

Silvia Zamboni

Auto-generated profile, based on publicly available information

Silvia Zamboni

Department of Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2005 in BMC Infectious Diseases
Verified
Journal Article
Open access
MFMichela Flego
Michela Flego
PBPaola Di Bonito
Paola Di Bonito
AAAlessandro Ascione
Alessandro Ascione
SZSilvia Zamboni
Silvia Zamboni
ACAlessandra Carattoli
Alessandra Carattoli
MCMaurizio Cianfriglia
Maurizio Cianfriglia
Background: Severe acute respiratory syndrome (SARS)-CoV is a newly emerging virus that causes SARS with high mortality rate in infected people. Successful control of the global SARS epidemic will require rapid and sensitive diagnostic tests to monitor its spread, as well as, the development of vaccines and new antiviral compounds including neutralizing antibodies that effectively prevent or treat this disease. Methods: The human synthetic single-chain fragment variable (scFv) ETH-2 phage antibody library was used for the isolation of scFvs against the nucleocapsid (N) protein of SARS-CoV using a bio panning-based strategy. The selected scFvs were characterized under genetics-molecular aspects and for SARS-CoV N protein detection in ELISA, western blotting and immunocytochemistry. Results: Human scFv antibodies to N protein of SARS-CoV can be easily isolated by selecting the ETH-2 phage library on immunotubes coated with antigen. These in vitro selected human scFvs specifically recognize in ELISA and western blotting studies distinct epitopes in N protein domains and detect in immunohistochemistry investigations SARS-CoV particles in infected Vero cells. Conclusion: The human scFv antibodies isolated and described in this study represent useful reagents for rapid detection of N SARS-CoV protein and SARS virus particles in infected target cells.